Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis.
Nassar A, Matteson K, Ardeshir F, Gray J, Baena Espinar J, Kwiatkowski D, Aboubakar Nana F, Grohe C, Citarella F, Pancirer D, Cheung J, Watson A, Sridhar A, Crowley F, Kaldas D, Kim C, Sankar K, Awosika N, Naqash A, Chiang A. Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis. Journal Of Clinical Oncology 2024, 42: 8106-8106. DOI: 10.1200/jco.2024.42.16_suppl.8106.Peer-Reviewed Original ResearchLarge cell neuroendocrine carcinomaProgression-free survivalTreatment-related adverse eventsPD-L1 statusOverall survivalPD-L1Systemic therapyRetrospective analysisGrades treatment-related adverse eventsTreatment approachesCell neuroendocrine carcinomaMedian follow-upMulticenter retrospective analysisTreated with chemotherapySystemic treatment approachesChemo-regimenPlatinum-etoposideNeuroendocrine carcinomaOS outcomesLine treatmentToxicity profileClinical outcomesAdverse eventsImmunotherapyIO groupComparison of chemotherapy to chemo-immunotherapy as first-line treatment in patients with advanced large cell neuroendocrine carcinomas (LCNECs) of mixed histology: A multi-institutional international retrospective study.
Matteson K, Nassar A, Ellis-Caleo T, Mingo E, Aggarwal V, Sridhar A, Alam S, Crowley F, Aboubakar Nana F, Ahmed M, Grohe C, Zurera Berjaga M, Pinato D, Watson A, Chiang A, Naqash A. Comparison of chemotherapy to chemo-immunotherapy as first-line treatment in patients with advanced large cell neuroendocrine carcinomas (LCNECs) of mixed histology: A multi-institutional international retrospective study. Journal Of Clinical Oncology 2024, 42: 8602-8602. DOI: 10.1200/jco.2024.42.16_suppl.8602.Peer-Reviewed Original ResearchProgression-free survivalTreatment-related adverse eventsFirst-line treatmentMedian progression-free survivalOverall survivalChemo-immunotherapyMedian OSLung cancerAll-grade treatment-related adverse eventsRare subtype of lung cancerMulti-institutional retrospective analysisSmall cell lung cancerCell neuroendocrine carcinomaInternational retrospective studyCell lung cancerSubtype of lung cancerLog-rank testFeatures of adenocarcinomaOptimal treatment approachClinical trial dataChemo-regimensNeuroendocrine carcinomaChemo groupSystemic therapyRare subtype